Search results
Results from the WOW.Com Content Network
One of the most notable scientific papers that first popularized hydroxychloroquine as a COVID-19 treatment was retracted from its journal due to ethical and methodological issues. Retractions in ...
The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19. [146] [147] Following Trump's claim, panic buying of chloroquine was reported from many countries in Africa, Latin America and South Asia. Health ...
"Guidelines on the Treatment and Management of Patients with COVID-19". Infectious Diseases Society of America (IDSA). "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines". National Institutes of Health. World Health Organization. Corticosteroids for COVID-19: living guidance, 2 September 2020 (Report). hdl: 10665/334125. WHO/2019-nCoV ...
Famotidine has been suggested as a treatment for COVID-19, [33] and a clinical study is underway. [230] Ibuprofen: A trial called "Liberate" has been started in the United Kingdom to determine the effectiveness of ibuprofen in reducing the severity and progression of lung injury which results in breathing difficulties for COVID-19 patients ...
At an unusually contentious briefing Thursday of the coronavirus task force, President Trump floated the idea that people infected with COVID-19 might be treated using injections of disinfectant ...
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
Killing coronavirus: U.S. Environmental Protection Agency has released a list of disinfectants and wipes to protect against spread of the coronavirus.
Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.